{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-23-001383","form_type":"8-K","ticker":"GTHP","cik":"0000924515","company_name":"GUIDED THERAPEUTICS INC","filed_at":"2023-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.611061+00:00","generated_at":"2026-06-18T08:07:50.739379+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Guided Therapeutics CEO Gene Cartwright retires; Mark Faupel appointed as successor","bullets":["Gene Cartwright retired as President, CEO, and Board member effective March 3, 2023; no disagreement cited.","Board appointed COO Dr. Mark Faupel (Ph.D., 67) as President and CEO effective March 6, 2023; he was CEO from 2007-2013.","Alan Grujic appointed to Board effective March 8, 2023; brings finance and hedge fund experience.","Faupel's compensation as CEO to be determined later by compensation committee.","Grujic is not appointed to any Board committees; no related-party transactions disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-23-001383","json":"https://secwatch.observer/filing/0001477932-23-001383.json","markdown":"https://secwatch.observer/filing/0001477932-23-001383.md","text":"https://secwatch.observer/filing/0001477932-23-001383.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/924515/000147793223001383/0001477932-23-001383-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/924515/000147793223001383/gthp_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T08:07:50.739379+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5cd25692ac","claim":"Alan Grujic was appointed as Director at GUIDED THERAPEUTICS INC.","evidence_excerpt":"the Board appointed Mr. Alan Grujic to replace Mr. Cartwright on the Board, effective March 8, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/924515/000147793223001383/0001477932-23-001383-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"63d9b63eb2","claim":"Gene Cartwright retired as President and Chief Executive Officer at GUIDED THERAPEUTICS INC.","evidence_excerpt":"Dr. Gene Cartwright notified the Board of Directors (the “ Board ”) of Guided Therapeutics, Inc. (the “ Company ”) of his intent to retire from his position as President and Chief Executive Officer of the Company and as a member of the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/924515/000147793223001383/0001477932-23-001383-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"aed0fa59f9","claim":"Mark Faupel was appointed as President and Chief Executive Officer at GUIDED THERAPEUTICS INC.","evidence_excerpt":"the Board appointed Dr. Mark Faupel, Ph.D., 67, the Company’s Chief Operating Officer since December 2016, to replace Mr. Cartwright as the Company’s President and Chief Executive Officer, effective as of March 6, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/924515/000147793223001383/0001477932-23-001383-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}